source
- STAT+: An insider reveals the real goals of prior authorizationYears ago, Archelle Georgiou helped squash prior auths at one of America's biggest health insurers.STAT · 3mo ago↗ source
- Lilly to buy startup Ajax in bid for a better JAK drugWorth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.BioPharma Dive · 3mo ago↗ source
- STAT+: Astellas retries XLMTM gene therapy after deathsVeradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech newsSTAT · 3mo ago↗ source